It's no secret that pharmaceutical companies are having problems filling their pipelines, says Pharmalot's Ed Silverman. On top of slashing R&D budgets, many companies are now finding that the cost of clinical trials is on the rise, across all phases. "There is increasing competition for trial sites and clinical research organizations that can yield reliable, high quality data," Silverman says.